{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "CRL",
  "name": "Charles River Laboratories International, Inc.",
  "url": "https://frontierpicks.com/dossiers/CRL/",
  "json_url": "https://frontierpicks.com/dossiers/CRL.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Post-2026-08-05 demand-recovery leg extended to a new 52wk high at the 2026-08-21 close of $295.19 (RSI 86.6, +84.1% over three months) with no rating action since TD Cowen's $300 on 08-10 — price is now inside the $282-$310 target band. The newly dated 2026-09-24 Investor Day, where long-term financial targets get reset, is the next test.",
  "invalidation_trigger": "A weekly close below $263 unwinds the entire post-2026-08-05 print advance (the first post-print insider disposition printed at $263.00 on 08-05); secondary, the 2026-09-24 Investor Day passing without a raised long-term financial target framework, or Q3 DSA net bookings below $701M sequentially.",
  "catalyst_date": "2026-09-24",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Next earnings is the Q3 2026 print, expected early November; nothing company-scheduled falls inside 30 days of 2026-08-23 apart from the 2026-09-24 Investor Day at 32 days.",
    "FY2026 guides diverge sharply: GAAP EPS $3.05-$3.35 vs non-GAAP $11.15-$11.45, both set 2026-08-05. Screening on the wrong line changes the multiple entirely.",
    "Reported revenue still shrinks in 2026 on divestitures (~7% of 2025 revenue exited). Organic is the only comparable growth series.",
    "RMS carries direct NIH and academic-funding exposure; management reiterated lower North America research-model volumes on 2026-08-05.",
    "Several August 2026 insider sales ran under Rule 10b5-1 plans (Parisotto's adopted 2026-03-04, Girshick's 2025-03-03), so timing was pre-scheduled rather than discretionary.",
    "The May 2025 Elliott cooperation agreement and refreshed board remain in place; the 2026-09-24 Investor Day is the first scheduled reset of long-term targets under it."
  ],
  "body_markdown": "## Current Thesis\nThe last note closed on a gap: the demand-recovery story had been confirmed on 2026-08-05, the sell-side had repriced it inside six days, and then nothing dated stood between the stock and an early-November Q3 print. That gap has been filled. Management has set an Investor Day for **2026-09-24 at 9:00 a.m. ET**, webcast from ir.criver.com, at which it has said it will lay out long-term priorities and financial targets — the first scheduled reset of the long-term framework since the May 2025 Elliott cooperation agreement.\n\nPrice moved ahead of it. The 2026-08-21 close of $295.19 is a new 52-week high, 5.4% above the 2026-08-14 close of $280.05 and 84.1% higher over three months, with RSI(14) at 86.6 against 83.4 a week earlier. That advance carried no new rating action behind it: the upgrade wave ran 2026-08-06 to 2026-08-10 and stopped. The narrative leg an investor is buying today is no longer \"does demand come back\" — Q2 answered that with DSA net bookings of $701M, net book-to-bill 1.19x and the first organic growth in nine quarters. It is \"does the September framework put a number on 2027–2028 that the $300 target cluster does not already contain.\"\n\n## Bull Case\n- **The catalyst is now dated.** Investor Day 2026-09-24, 9:00 a.m. ET. Management said on the 2026-08-05 call it will detail long-term priorities and financial targets there. Every prior version of this story had an Investor Day referenced without a date; it now has one inside six weeks.\n- **Bookings, not proposals.** DSA net bookings $701M (+12.6% sequential), net book-to-bill 1.19x, backlog $1.97B, all reported 2026-08-05 — highest bookings and book-to-bill since Q3 2022 and a third consecutive quarter above 1.0x. Backlog is the mechanism that converts a demand statement into 2027 revenue.\n- **The inflection is measured, not guided.** Q2 2026 organic revenue +0.1% and DSA organic +0.2%, ending a nine-quarter contraction. FY2026 organic guidance was raised 150bps to flat-to-+1%.\n- **Both guide lines moved on the non-GAAP series.** FY2026 non-GAAP EPS lifted to $11.15–$11.45 from $10.80–$11.30 against an $11.12 consensus; FY2026 sales to $3.879–$3.920B from $3.794–$3.854B against $3.850B.\n- **Customer funding is present.** Management cited roughly $100B of trailing-twelve-month biotech funding on the 2026-08-05 call, described as near pandemic-era peaks, with demand broad-based across IND-enabling and NHP work.\n- **Manufacturing Solutions margin.** 37.8% operating margin in Q2 2026, +500bps year over year, on $188M revenue.\n- **Fresh commercial datapoint.** On 2026-08-20 the company announced a collaboration with Medigen Vaccine Biologics on characterization and validation of a virus seed bank for MVC's next-generation multivalent enterovirus vaccine. No financial terms disclosed — the relevance is that biologics testing work is still being signed post-print.\n\n## Bear Case\n- **Price has walked into the target band.** The 2026-08-21 close of $295.19 is 4.7% above RBC's $282 (2026-08-06) and 1.6% below the $300 cluster shared by Evercore ISI (2026-08-06), Morgan Stanley (2026-08-07) and TD Cowen (2026-08-10). JP Morgan's $310 (2026-08-06) leaves 5.0%. Analyst-rating aggregators also reported Mizuho lifting to $264 from $230 on 2026-08-10; that figure sits 11.8% under the 08-21 close.\n- **Consensus has not caught up on paper.** An aggregator computation published 2026-08-18 put the brokerage-average target at $255.65 — below the market price, because it blends targets that have not been refreshed since the print. Whether the average rises or the price falls to meet it is the open question.\n- **Insider distribution extended and stepped higher.** Six dispositions between 2026-08-05 and 2026-08-18, each at a higher print: Parisotto 5,046 sh at $263.00 (08-05); Knell exercise-and-sell at $258.53 (08-06); Girshick 6,500 options exercised at $179.66 and sold at $279.90 (08-11); Andrews 573 options at $164.30 sold at $285.24 (08-18, filed 08-20). Several ran under pre-adopted Rule 10b5-1 plans, so the timing was scheduled — the supply is real either way.\n- **The GAAP line went the other direction.** The same 2026-08-05 release cut FY2026 GAAP EPS guidance to $3.05–$3.35 from $5.35–$5.85, against a $6.24 consensus.\n- **RMS is still contracting.** Organic -1.4% in Q2 2026, with management reiterating lower North America research-model volumes and academic/government spending constrained by flat NIH budgets.\n- **Segment margins have not turned.** DSA operating margin 25.6% (-180bps YoY) and RMS 24.5% (-80bps YoY) in Q2, even as consolidated margin reached 20.5%.\n- **Attention shape.** A 2026-08-14 Benzinga piece ran the fifteen-year-return retrospective format, quoting a $14.32B market capitalisation. That kind of backward-looking coverage appears after a move has been noticed, not while it is being discovered.\n\n## Setup & Price Structure\n- The reference close for grading is $295.19 on 2026-08-21 — the 52-week high itself, 0.0% below it, RSI(14) 86.6.\n- The post-print floor is documented by the Form 4 record rather than by any chart supplied here: the first two sessions after 2026-08-05 saw insider sales at $263.00 and $258.53. From $263.00 the stock is 12.2% higher; from $258.53, 14.2%. The whole of that advance happened without a new company disclosure between 2026-08-11 and the 2026-08-20 Medigen release.\n- Distance above the most recent insider print: the 08-21 close is 3.5% above the $285.24 director sale of 2026-08-18.\n- **The narrative is maturing.** The narrative is well known and still working — the stock made a new high on 2026-08-21 — but the flow behind it is moderating. The rating actions all fall in a five-day window ending 2026-08-10; the 5.4% advance from 08-14 to 08-21 came with none. Coverage has shifted from event reporting to retrospective performance pieces (2026-08-14). What would flip the label to saturated: the 2026-09-24 Investor Day passing without a raised long-term target framework while price holds near the high, or the first valuation-driven downgrade from the five firms that moved in August.\n- Crowding observables, stated without a verdict: RSI(14) 86.6 at the 52-week high; +84.1% over three months; six insider dispositions in ten trading sessions at successively higher prices; published targets clustered at $282–$310 with the market price inside that band; no earnings date inside 30 days.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-09-09 (est., unannounced)** — early-September investor conferences. In 2025 the company presented at the Morgan Stanley Global Healthcare Conference on 09-09 and the Baird Global Healthcare Conference on 09-10. No 2026 equivalent has been announced as of 2026-08-23; treat the dates as pattern, not schedule.\n- **2026-09-24, 9:00 a.m. ET** — Investor Day, webcast at ir.criver.com. Long-term priorities and financial targets. Falls 32 days out, just past the 30-day window, and is the nearest dated company event.\n- **2026-10-01** — start of US federal fiscal year 2027 / NIH appropriations outcome. Sets the academic and government demand backdrop for RMS.\n- **~2026-11-04 (est.)** — Q3 2026 earnings. The only test of whether $701M DSA net bookings and 1.19x book-to-bill extend.\n\n## What Would Change Our Mind\nThe structural break is the September framework. If the 2026-09-24 Investor Day arrives and the long-term targets it publishes are already inside the $282–$310 band the Street set in August, the event resolves as a non-event and the leg has to be carried by Q3 alone, six weeks later. That is the date to grade first.\n\nThe gradeable price condition: a weekly close below $263 unwinds the entire post-2026-08-05 advance, back to where the first post-print insider disposition printed at $263.00 on 2026-08-05 — at which point the market has decided the bookings quarter was a catch-up rather than a run-rate.\n\nThree fundamental conditions would break the thesis independently of price: Q3 2026 DSA net bookings below the $701M Q2 level sequentially, or net book-to-bill under 1.0x after three quarters above it; a second reduction to GAAP EPS guidance or a new impairment disclosed alongside the Q3 print; RMS organic still negative at Q3 with the same North America volume and NIH commentary given on 2026-08-05.\n\n## Correlation Notes\n- Preclinical and clinical CRO complex — ICLR, IQV, and the bioproduction lines at TMO and DHR. The 1.19x book-to-bill reported 2026-08-05 is an industry-level datapoint, so peer bookings disclosures in the October–November reporting window read directly onto this thesis.\n- Small and mid-cap biotech funding is the demand input management named on 2026-08-05 (~$100B trailing twelve months). XBI is the observable proxy; the funding series is rate-sensitive, so a repricing of Fed expectations transmits to CRL's customer base with a lag rather than immediately.\n- RMS carries direct US federal exposure. NIH appropriations for FY2027 (from 2026-10-01) and any continuing-resolution outcome bear on a segment that ran -1.4% organic in Q2 2026.\n- NHP supply chain — non-human-primate sourcing and import policy remains an idiosyncratic input to DSA capacity and pricing that does not correlate with the broader healthcare tape.\n- Inferred, not measured: with the stock 84.1% higher over three months and RSI(14) at 86.6, short-horizon behaviour is more likely to track momentum-factor flows than CRO fundamentals until the 2026-09-24 event supplies new information.",
  "first_seen": "2026-07-24",
  "last_analyzed": "2026-08-23T12:41:21+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}